{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:01:06Z","timestamp":1780678866753,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20392"],"award-info":[{"award-number":["U20A20392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["D20028"],"award-info":[{"award-number":["D20028"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303600"],"award-info":[{"award-number":["2022YFA1303600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.117983","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:57:55Z","timestamp":1776322675000},"page":"117983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Antiviral activity of novel chemical compound 0411, derived from FUBP1-IN-1 against hepatitis B virus by upregulation of DUSP5"],"prefix":"10.1016","volume":"250","author":[{"given":"Shuang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisha","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-0920","authenticated-orcid":false,"given":"Hui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.117983_b0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2026.117983_b0015","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0020","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","article-title":"Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between Seroclearance of Hepatitis B Surface Antigen and long-term Clinical Outcomes of patients with Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117983_b0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"2017 Clinical Practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Easl","year":"2017","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(\u2021)","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117983_b0040","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.bcp.2026.117983_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005893","article-title":"DNA Polymerase \u03ba is a Key Cellular factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus","volume":"12","author":"Qi","year":"2016","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-virology-110615-042238","article-title":"The Structural Biology of Hepatitis B Virus: form and Function","volume":"3","author":"Venkatakrishnan","year":"2016","journal-title":"Annu. Rev. Virol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.117983_b0055","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1136\/gutjnl-2012-302056","article-title":"New insight in the pathobiology of hepatitis B virus infection","volume":"61","author":"Dandri","year":"2012","journal-title":"Gut"},{"issue":"47","key":"10.1016\/j.bcp.2026.117983_b0060","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0042-6822(90)90206-7","article-title":"In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway","volume":"175","author":"Wu","year":"1990","journal-title":"Virology"},{"issue":"16","key":"10.1016\/j.bcp.2026.117983_b0070","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/acs.jmedchem.6b00879","article-title":"Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine based Hepatitis B Virus (HBV) Capsid Inhibitors","volume":"59","author":"Qiu","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.117983_b0075","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"issue":"587","key":"10.1016\/j.bcp.2026.117983_b0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.117983_b0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2011.12.032","article-title":"Peginterferon-\u03b1 does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis","volume":"56","author":"Penna","year":"2012","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117983_b0090","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bcp.2026.117983_b0095","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/jgh.14534","article-title":"Okuda lecture: challenges of hepatitis B in the era of antiviral therapy","volume":"34","author":"Chan","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"24","key":"10.1016\/j.bcp.2026.117983_b0105","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1038\/onc.2012.350","article-title":"Far upstream element binding protein 1: a commander of transcription, translation and beyond","volume":"32","author":"Zhang","year":"2013","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.bcp.2026.117983_b0110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00439-18","article-title":"Adenovirus 5 E1A-mediated suppression of p53 via FUBP1","volume":"92","author":"Frost","year":"2018","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117983_b0115","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1128\/JVI.01950-10","article-title":"FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication","volume":"85","author":"Chien","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2026.117983_b0120","unstructured":"Souphalone Luangsay BCaT, Lyons(FR);Fabienoulim,Lyons(FR);Soren Ottosen,orsholm (DK);Lykke Pedersen,orsholm (DK), inventorUse of FUBP1 inhibitors for treating hepatitis B virus infection. US2023."},{"issue":"4","key":"10.1016\/j.bcp.2026.117983_b0125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41419-022-04852-3","article-title":"PRKDC promotes hepatitis B virus transcription through enhancing the binding of RNA Pol II to cccDNA","volume":"13","author":"Fan","year":"2022","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.bcp.2026.117983_b0130","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1128\/jvi.66.7.4107-4116.1992","article-title":"The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly","volume":"66","author":"Nassal","year":"1992","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.bcp.2026.117983_b0135","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.bmc.2016.09.015","article-title":"Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors","volume":"24","author":"Hauck","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.117983_b0140","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/MCB.25.5.1830-1845.2005","article-title":"Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5","volume":"25","author":"Mandl","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117983_b0145","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4049\/jimmunol.177.11.7497","article-title":"DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response","volume":"177","author":"Lang","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","article-title":"Lateral Thinking: how Histone modifications Regulate Gene Expression","volume":"32","author":"Lawrence","year":"2016","journal-title":"Trends Genet."},{"issue":"14","key":"10.1016\/j.bcp.2026.117983_b0155","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1128\/JVI.01024-14","article-title":"Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice","volume":"88","author":"Qi","year":"2014","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.117983_b0165","unstructured":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3(6):383-403."},{"issue":"5","key":"10.1016\/j.bcp.2026.117983_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097579","article-title":"AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bcp.2026.117983_b0175","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.117983_b0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2026.117983_b0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.117983_b0190","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.bcp.2026.117983_b0195","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis B virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117983_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.bcp.2026.117983_b0210","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in patients with Chronic HBV Infection Na\u00efve to Nucleos(t)ide Therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.26339","article-title":"Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance","volume":"58","author":"Lan","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.bcp.2026.117983_b0225","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1021\/bi9021445","article-title":"Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR","volume":"49","author":"Hsiao","year":"2010","journal-title":"Biochemistry"},{"issue":"23\u201324","key":"10.1016\/j.bcp.2026.117983_b0230","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1002\/pmic.200800322","article-title":"2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis","volume":"8","author":"Zubaidah","year":"2008","journal-title":"Proteomics"},{"issue":"5","key":"10.1016\/j.bcp.2026.117983_b0235","first-page":"2019","article-title":"Role of far upstream element binding protein 1 in colonic epithelial disruption during dextran sulphate sodium-induced murine colitis","volume":"7","author":"Tang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117983_b0240","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00432-010-0812-0","article-title":"Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis","volume":"136","author":"Xu","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.bcp.2026.117983_b0245","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/jm0497803","article-title":"NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter","volume":"47","author":"Huth","year":"2004","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0250","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20082234","article-title":"Dual-specificity phosphatases: critical regulators with diverse cellular targets","volume":"418","author":"Patterson","year":"2009","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bcp.2026.117983_b0255","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1006\/geno.1994.1411","article-title":"Chromosomal localization of four human VH1-like protein-tyrosine phosphatases","volume":"22","author":"Martell","year":"1994","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.bcp.2026.117983_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030678","article-title":"Emerging Regulatory Roles of Dual-Specificity Phosphatases in Inflammatory Airway Disease","volume":"20","author":"Manley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117983_b0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fphys.2012.00355","article-title":"Crosstalk and signaling switches in mitogen-activated protein kinase cascades","volume":"3","author":"Fey","year":"2012","journal-title":"Front. Physiol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117983_b0270","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","article-title":"Metabolic reprogramming and epigenetic modifications on the path to cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.117983_b0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-022-01078-9","article-title":"The role of histone modifications: from neurodevelopment to neurodiseases","volume":"7","author":"Park","year":"2022","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:10:52Z","timestamp":1780675852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"alternative-id":["S0006295226003163"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117983","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral activity of novel chemical compound 0411, derived from FUBP1-IN-1 against hepatitis B virus by upregulation of DUSP5","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117983"}}